you

Learn about the latest news from the BIG network:
For over 20 years, BIG has been conducting global breast cancer trials and research programmes.
Many are considered to be landmark, introducing particularly innovative designs, contributing to significant breakthroughs, or paving the way towards more personalised treatment of breast cancer.
Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.
These studies hold tremendous potential for patients and promise long-term gains for society, in all regions of the world
EXPERT –
BIG radio tuning
Aims to tailor the use of radiotherapy according to each patient’s risk of breast cancer relapse, ultimately hoping to identify those patients who can safely avoid this treatment. The results of this study could influence how 2 in 5 women with breast cancer are treated in the future.
POSITIVE –
BIG time for baby
Aims to evaluate whether it is safe for women to interrupt their endocrine therapy to try to conceive after breast cancer. This has been a terrible dilemma to young women wishing to have a child. If treatment is stopped to try to conceive, will it increase the risk of cancer recurrence? This is the kind of question the study intends to address.
AURORA –
Metastatic breast cancer GPS
Aims to improve our understanding of metastatic breast cancer, to identify genetic breakdowns, and to map the routes that cancer cells take to invade other organs. Its first phase recently completed and a second is being launched to focus on specific subtypes of the disease that are particularly aggressive.
Donate
94,4% of all funds received by BIG in 2020, including funds raised by BIG against breast cancer, went directly to BIG's research.
Attend an event
By attending a BIG event, you're not only creating memories, you're also supporting BIG's academic studies.
Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.
Co-funded by the European Union under an operating grant from the European Union’s EU4Health programme under grant agreement No 101124555. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.